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Abstract
The prostaglandin endoperoxide synthase (PTGS) pathway is a potent driver of tumour development in humans by
enhancing the biosynthesis and signalling of prostaglandin (PG) E2. PTGS2 expression and PGE2 biosynthesis is elevated in
endometrial adenocarcinoma, however the mechanism whereby PTGS and PGE2 regulate endometrial tumour growth is
unknown. Here we investigated (a) the expression profile of the PGE synthase enzymes (PTGES, PTGES-2, PTGES-3) and PGE
receptors (PTGER1–4) in endometrial adenocarcinomas compared with normal endometrium and (b) the role of PTGER4 in
endometrial tumorigenesis in vivo. We found elevated expression of PTGES2 and PTGER4 and suppression of PTGER1 and
PTGER3 in endometrial adenocarcinomas compared with normal endometrium. Using WT Ishikawa endometrial
adenocarcinoma cells and Ishikawa cells stably transfected with the full length PTGER4 cDNA (PTGER4 cells) xenografted
in the dorsal flanks of nude mice, we show that PTGER4 rapidly and significantly enhances tumour growth rate. Coincident
with enhanced PTGER4-mediated tumour growth we found elevated expression of PTGS2 in PTGER4 xenografts compared
with WT xenografts. Furthermore we found that the augmented growth rate of the PTGER4 xenografts was not due to
enhanced angiogenesis, but regulated by an increased proliferation index and hypoxia. In vitro, we found that PGE2 and
hypoxia independently induce expression of PTGER4 indicating two independent pathways regulating prostanoid receptor
expression. Finally we have shown that PGE2 and hypoxia synergise to promote cellular proliferation of endometrial
adenocarcinoma cells.
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Introduction
Endometrioid adenocarcinoma arising from the endometrial
glandular epithelium is one of the leading causes of cancer-related
morbidity in women world-wide [1,2]. The onset of the disease
occurs more frequently post menopause and is associated with a
host of risk factors, including high levels of unopposed estrogen,
endometrial hyperplasia and obesity [1].
Although the molecular mechanisms responsible for the
initiation of the disease are multifactorial, there is now much
evidence to substantiate genetic alterations and the inactivation of
tumour suppressor genes in the neoplastic transformation of cells
to facilitate uncontrolled proliferation and tumour growth [3].
Indeed one of the most common mutations in endometrial
adenocarcinomas is located in the dual specificity phosphatase
PTEN (phosphatase and tensin homologue deleted from chromo-
some ten) gene [2]. Animal models in which PTEN expression is
inactivated in the endometrium have shown that loss of the PTEN
function rapidly and unfailingly induces endometrial cancer [4].
Inactivation of PTEN function promotes protein kinase B (also
called Akt) activation which in turn stimulates the activity of
several target genes involved in cell proliferation [5]. One the
major targets of Akt signalling in endometrial adenocarcinoma
cells, is prostaglandin endoperoxide synthase (PTGS) 2 (also called
cyclooxygenase 2) [4,6].
PTGS2 converts arachidonic acid, the rate limiting substrate in
the prostaglandin biosynthesis cascade to the unstable intermedi-
ate prostaglandin (PG)G2 which is subsequently converted to
PGH2 [7]. In turn PGH2 is metabolised by terminal prostaglandin
synthase enzymes, which are named according to the prostaglan-
din they biosynthesise. For example prostaglandin E synthase
(PTGES) enzymes, of which there are three isoforms (PTGES,
PTGES-2, PTGES-3) produce PGE2 [8]. PTGS2 expression is
elevated in numerous neoplastic diseases including endometrial
adenocarcinomas resulting in elevated biosynthesis of PGE2
[9,10]. In vitro and in vivo model systems overexpressing PTGS2
have shown that PGE2 can promote tumorigenesis by altering cell
cycle progression, inhibiting apoptosis and enhancing cellular
proliferation [11,12,13]. Furthermore PGE2 can promote tumour
progression by down-regulating tumour suppressor genes such as
tuberous sclerosis-2 (TSC2) [14], P53 and retinoblastoma in
epithelial cells [11].
Following biosynthesis, PGE2 is transported out of the cell
where it binds to and activates PGE2 G protein-coupled receptors
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expression is elevated in numerous cancers where it can transduce
pathways important for cancer cell survival and tumour
progression, such as the Akt, extracellular signal regulated kinase
(ERK1/2) and early growth response factor-1 [16,17,18]. The aim
of this study was to identify the components of the PTGS-PGE2
pathway in endometrial adenocarcinomas which regulate tumour
growth.
Here, we show suppression of PTGER1 and PTGER3 and
elevated expression of PTGES2 and PTGER4 in endometrial
adenocarcinomas compared with normal endometrium. We show
that inoculation of nude mice with Ishikawa endometrial
adenocarcinoma cells stably expressing PTGER4 promotes
formation of tumour xenografts which grow at a significantly
faster rate compared with tumours arising from WT control cells.
Moreover these tumours displayed elevated expression of PTGS2
compared with tumours arising from WT Ishikawa cells.
Morphometric and stereological analyses showed no difference
in blood vessel density or VEGF expression in PTGER4 tumours
compared with WT tumours indicating that PTGER4-mediated
tumour growth was not a result of increased angiogenesis. The
PTGER4 tumours displayed an increase in cellular proliferation
and increased areas of hypoxia. Using in vitro models, we
subsequently demonstrated that hypoxia and PGE2 synergise to
induce expression of PTGER4 leading to increased cellular
proliferation.
Materials and Methods
Ethics Statement
Ethical approval was obtained from Lothian Research Ethics
Committee (LREC/07/S1103/32, LREC/05/S1103/29 and
LREC/1999/6/4) and written informed consent was obtained
from all subjects before tissue collection. All animal care and
experimental protocols were approved by the animal ethics
committee of the University of Edinburgh and the Home Office
of the United Kingdom government under the guidelines of the
Animals (Scientific Procedures) Act 1986.
Human tissue
Poorly (grade 3; n=10), moderately (grade 2; n=10) and well
(grade 1; n=9) differentiated endometrial adenocarcinoma tissues
with clinical characteristics as described in Table 1 [19] were
collected from women undergoing hysterectomy. All women had
been pre-diagnosed on endometrial biopsy to have endometrial
adenocarcinoma of the endometrioid type. The diagnosis of
endometrial adenocarcinoma was confirmed histologically in all
cases as defined in Table 1 and the percentage of tumour cells to
stroma was estimated to be not less than 75%:25%. Normal
endometrium with clinical parameters as outlined in Table 2 from
the proliferative (n=10), early secretory (n=10), mid secretory
(n=10) and late secretory (n=10) phases of the menstrual cycle,
was collected from women undergoing surgery for gynecological
procedures in whom histological examination of endometrium was
normal with no underlying endometrial pathology (Pipelle,
Laboratoire CCD, France). All biopsies were dated according to
stated last menstrual period (LMP) and confirmed by hormone
analysis and histological assessment according to the criteria of
Noyes et al. [20].
Cell culture
Wild-type (WT) Ishikawa cells (European Collection of Cell
Culture, Wiltshire, UK) were maintained as described previously
[14]. Stable PTGER4 transfectant cells (PTGER4 cells) were
maintained under the same conditions with the addition of a
maintenance dose of 200 mg/ml G418 (Calbiochem, UK).
PTGER4 amplification and Cell Transfections
The PTGER4 receptor cDNA clone and stable cell lines were
constructed by Cytomix Ltd (Cambridge, UK). PTGER4 cDNA
(GenBank Accession N0. D28472) was amplified by polymerase
chain reaction (PCR) and the product was directionally cloned into
the mammalianexpressionvectorgWIZ3.0(Gene TherapySystems,
Cambridge, UK) at the Hind III and Bam H1 restriction sites and the
orientation of the construct confirmed by automated DNA
sequencing. The PTGER4 cDNA was transfected into Ishikawa
cellsandindividualcellpopulationswereselectedforwithadditionof
800 mg/mlG418.Fullselectionwasconfirmedbythe100%deathof
non-transfected control cells and five single PTGER4 sense clones
were selected and expanded for Western blot analysis. The clones
with the highest level of PTGER4 expression were expanded and
Table 1. Clinical parameters and tumour characteristics for
well (n=10), moderately (Mod, n=10) and poorly
differentiated (n=10) endometrial adenocarcinomas.
SAMPLE NO GRADE FIGO STAGE
1 Well Ib
2 Well Ib
3 Well Ia
4 Well Ic
5 Well IIIa
6 Well Ib
7 Well Ib
8 Well Ib
9 Well Ia
10 Mod Ic
11 Mod Ic
12 Mod Ia
13 Mod Ib
14 Mod IIb
15 Mod Ib
16 Mod Ic
17 Mod IIb*
18 Mod IIIa
19 Mod Ib
20 Poor Ia
21 Poor IIIa
22 Poor Ib
23 Poor Ib
24 Poor IIIa
25 Poor Ib
26 Poor Ib
27 Poor IIIa
28 Poor IIIa
29 Poor IIb*
All endometrial adenocarcinomas studied were of pure or predominantly of
endometrioid type. There were no pure serous or clear cell subtypes in the
series and none of the tumours showed carcinosarcoma.
*in these two samples myometrial invasion was ,50%.
doi:10.1371/journal.pone.0019209.t001
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PTGER4 expression, two sense clones (S20 and S22) exhibiting
similar phenotypic and biochemical alterations were supplied. The
results of our studies using the S22 clone are presented here.
cAMP Assay. PGE2 induced cAMP accumulation was
determined by seeding 2610
5 WT or PTGER4 cells/well in
6-well plates. The cells were serum-starved in the presence of
3 mg/ml of indomethacin. Thereafter, the cells were pre-treated
with the phosphodiesterase inhibitor 3-isobutyl-1-methyl xanthine
(IBMX; Sigma, Dorset, UK) to a final concentration of 0.2 mM in
serum-free medium for 30 min. Cells were treated for 5 min with
100 nM PGE2, or left unstimulated (time 0). After incubation the
cells were lysed in R&D Cell Lysis Buffer
TM (R&D Systems,
Oxford UK) and cAMP release was determined by ELISA using
cAMP Kit (R&D Systems) according to manufacturer’s protocol.
Data are represented as mean 6 SEM of three independent
experiments.
Xenograft Experiments. WT or PTGER4 cells (2.5610
6)
were subcutaneously injected in a volume of 100 ml into the left
and right flanks of ten CD1-Foxn1
nu mice (Charles River, Tranent,
UK). All animals were housed in individually ventilated cages.
The resulting tumours (n=20 WT tumours and n=20
PTGER4 tumours) were measured twice weekly by digital
calipers. Tumour volume was calculated using the formula;
Volume=0.56(vertical measurement/10)6(horizontal measure-
ment/10)6(horizontal measurement/10). After a period of 35
days, the animals were sacrificed. Two hours prior to sacrifice, the
animals received an intraperitoneal (i.p) injection of 50 mg/kg of
5-Bromo-deoxy Uridine (BrdU, Sigma, UK). One hour prior to
sacrifice, the animals received an i.p injection of 60 mg/kg of
Hypoxyprobe (pimonidazole hydrochloride; HPI, Inc, Burlington,
MA, USA). The tumours were removed and half of each was
placed in 4% neutral buffered formalin (NBF, Sigma, UK) and a
quarter section was snap-frozen in QIAzol (Qiagen, Crawley, UK)
for RNA extraction.
Quantitative RT-PCR. RNA from the tumours was
extracted using the RNeasy Mini Kit (Qiagen). RNA samples
were reverse-transcribed using VILO (Invitrogen, Paisley, UK)
according to the manufacturer’s guidelines. RT-PCR analysis of
the genes of interest was carried out using an ABI Prism 7500
(Applied Biosystems, Warrington, UK). Primer and FAM (6-
carboxyfluorescein)-labelled probe sequences are shown inTable 3.
For PTGES3, primer only amplification products were detected
using SYBR
TM Green (Applied Biosystems) incorporation during
the PCR reaction. Gene expression was normalised to 18S
ribosomal RNA (Applied Biosystems) as an internal standard.
Results are expressed relative to a standard (pooled normal human
endometrial tissue cDNA) included in all reactions. Data are
represented as mean 6 SEM.
Confocal Immunofluorescent microscopy. Approximately
1.0610
4 WT or PTGER4 cells were seeded in chamber slides and
fixed in 100% ice-cold methanol. Following fixing, cells were
washed in TBS (50 mM Tris-HCl, 150 mM NaCl pH 7.4) and
blocked using 5% normal swine serum diluted in TBS.
Subsequently, the cells were incubated with polyclonal rabbit
anti-PTGER4 antibody at a dilution of 1:50 at 4uC for 18 hours.
Control cells were incubated with rabbit immunoglobulin (IgG).
Thereafter, the cells were incubated with secondary swine anti-
rabbit tetramethyl rhodamine isothyocyanate (TRITC; Dako Corp,
High Wycombe, UK) at 25uC for 20 mins. Cells were then
mounted in Permafluor (Immunotech-Coulter, Buckinghamshire,
UK) and coverslipped prior to imaging.
Immunohistochemistry. Tumour tissue was embedded in
paraffin wax and sections of 5 mm thickness of WT (n=10) and
PTGER4 (n=10) tumours were cut and mounted on to coated
slides. The sections were de-waxed and rehydrated through graded
alcohols before antigen retrieval in 0.01 M citrate phosphate buffer.
Immunostaining was performed using the Vision Biosystems Bond
Immunostaining Robot (Leica Microsystems, Wezlar, Germany)
under normal operating conditions as described in our previous
study [21] using a sheep-anti-BrdU antibody (1:6000; Fitzgerald,
Table 2. Clinical parameters for normal endometrial samples
from proliferative phase, early secretory, mid secretory and
late secretory phase endometrium (n=10).
SAMPLE NO HISTOLOGY
PROGESTERONE
nmol/L
ESTRADIOL
pmol/L
1 Proliferative 4.26 339.38
2 Proliferative 2.22 641.37
3 Proliferative 4.62 525.00
4 Proliferative 4.57 495.00
5 Proliferative 2.82 214.00
6 Proliferative 1.78 400.00
7 Proliferative 4.80 204.00
8 Proliferative 3.12 731.00
9 Proliferative 2.32 1796.00
10 Proliferative 0.17 989.70
11 Early Secretory 63 353
12 Early Secretory 16.55 556
13 Early Secretory 63 458
14 Early Secretory 93.15 848
15 Early Secretory 9.03 90.43
16 Early Secretory 11.58 75.99
17 Early Secretory 10.371 876.16
18 Early Secretory 38.48 243.08
19 Early Secretory 26.74 768.92
20 Early Secretory 101.1 584
21 Mid Secretory 33.29 242.72
22 Mid Secretory 36.94 280.35
23 Mid Secretory 4.54 544.04
24 Mid Secretory 79.8 748
25 Mid Secretory 32.67 277
26 Mid Secretory 25.74 292
27 Mid Secretory 37.54 658
28 Mid Secretory 36.17 294.79
29 Mid Secretory 14.53 392
30 Mid Secretory 9.78 248.03
31 Late Secretory 0.47 0
32 Late Secretory 6.60 174.75
33 Late Secretory 8.36 326
34 Late Secretory 65.65 1075
35 Late Secretory 133.6 876
36 Late Secretory 3.85 55
37 Late Secretory 7.67 248.89
38 Late Secretory 20 410.91
39 Late Secretory 8.36 326
40 Late Secretory 65 1075
doi:10.1371/journal.pone.0019209.t002
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tems mouse polymer protocol at 1:50 dilution). For CD31, sections
were blocked in normal porcine serum and incubated with rabbit-
anti-CD31 (1:250; Abcam, Cambridge, UK) overnight at 4uC.
Sections were incubated with a 1:250 dilution of swine-anti-rabbit
biotinlyated secondary antibody (DAKO, Cambridge, UK). The
sections were then incubated with streptavidin peroxidase (1:1000)
and detected using 3-39 diaminobenzidine (DAB; DAKO) prior to
imaging.
Stereological analysis. Images were captured using a 640
plan apo objective from a BH2 microscope (Olympus, Tokyo,
Japan) fitted with an automatic stage (Prior Scientific Instruments
Ltd., Cambridge, UK) and video camera (HV-C20; Hitachi,
Tokyo, Japan) and were analyzed with Image-Pro Plus 4.5.1
software with a Stereology 5.0 plug-in (Media Cybernetics,
Wokingham, Berkshire, UK). 100 random fields of view were
counted for each tumour section (n=5 WT and PTGER4 tumour
sections for Hypoxyprobe counts, n=7 tumour sections each for
BrdU counts and n=11 tumour sections each for CD31 counts).
Hypoxia experiments. Ishikawa WT and PTGER4 cells
were plated at a density of 2.5610
5 cells per well in triplicate in 6
well plates. Cells were cultured under normoxic conditions (20%
oxygen) in a standard incubator at 37uC, 95% air/5% CO2 or
placed in hypoxia chamber (1% oxygen) at 37uC, 80% N2/10%
H2/10% CO2 for 24 hours in the presence/absence of 8.4 mM
indomethacin [22]. RNA was extracted, reverse transcribed and
PTGER4 expression was determined by quantitative RT-PCR as
described above. In the case of hypoxic cells, these manipulations
were performed inside the hypoxia chamber to avoid
reoxygenation. Data are represented as mean 6 SEM of four
independent experiments.
Proliferation assay. Ishikawa WT and PTGER4 cells were
plated at a density of 5.0610
3 cells per well in 96 well plates. The
following day cells were incubated in serum free medium in the
absence/presence of 8.4 mM indomethacin. Thereafter cells were
treated with vehicle or 1 mM PGE2 in the presence/absence of
indomethacin. Plates were incubated under normoxic or hypoxic
conditions as described above for 24 hours. Cell proliferation was
measured using the CellTitre96Aqueous One Solution
Proliferation Reagent (Promega, Southampton, UK) as per the
manufacturer’s protocol. Data are represented as mean 6 SEM of
four independent experiments.
Statistics. Data were analysed using an unpaired t-test or a
one-way ANOVA with Tukey’s multiple comparison post test
where applicable (GraphPad Prism, GraphPad Software Inc.,
USA). Box and whisker plots: Boxes represent the data lying
within the 5
th to the 95
th percentile and the whiskers represent the
minimum and maximum values.
Results
Expression profiling of the PGE2-PTGER signalling
pathway in endometrial adenocarcinomas
We recently undertook a comprehensive analysis of the
expression profile of the prostaglandin enzymes and receptors in
normal endometrium across the menstrual cycle [23]. Here, we
undertook a comprehensive analysis of the expression profile of the
PGE synthase enzymes (PTGES, -2, -3) and E-series prostanoid
receptors (PTGER1–4) in endometrial adenocarcinoma by
quantitative RT-PCR analysis (Figure 1 and Figure S1). We
found no significant difference in expression patterns of the
synthase enzymes or prostanoid receptors between the different
grades of endometrial adenocarcinoma investigated and hence-
forth pooled the data for analysis. We found elevated expression of
PTGES2 (P,0.01) and PTGER4 (P,0.01) in all grades of
endometrial adenocarcinomas compared with pooled normal
endometrium. Interestingly, within our sample set, the present
study revealed a significant decrease in the expression of PTGER1
(P,0.001) and PTGER3 (P,0.001), which are reported to
differentially couple to Gq/11 and Gi proteins and which
mobilises intracellular calcium and suppresses cAMP respectively.
These results indicate a bias towards the PGE2-PTGER4-cAMP
pathway as a potential driver of endometrial cancer.
PTGER4 enhances growth of tumour xenografts in vivo
In endometrial adenocarcinomas, PTGER4 is localised to the
neoplastic epithelial compartment [9]. To elucidate a role for the
PGE2-PTGER4-cAMP pathway in endometrial tumour growth,
we stably transfected Ishikawa endometrial epithelial cells with the
full length PTGER4 cDNA transcript. Quantitative RT-PCR
analysis showed elevated PTGER4 expression in PTGER4 cells
compared with WT cells (Figure 2A, P,0.001). Using immuno-
histochemistry and confocal laser microscopy, we localised the site
of expression of the translated PTGER4 transgene to the plasma
membrane compartment (Figure 2B).
PTGER4 couples to Gs resulting in increased cAMP accumu-
lation. We assessed functionality of the transfected PTGER4
cDNA transcript by cAMP ELISA in response to treatment with
100 nM PGE2 for 5 minutes. A significant increase in cAMP
accumulation was observed in PTGER4 cells compared with WT
cells following treatment with PGE2 (Figure 2C, P,0.05).
To assess the role of PTGER4 in endometrial cell tumorigenesis
in vivo, we xenografted either WT cells or PTGER4 cells into the
dorsal flanks of CD1-Foxn1
nu mice and measured the resulting
tumour growth over a 35 day period. We found a significant
divergence in the growth rate of the tumours arising from the
respective cell types, with PTGER4 xenograft tumours growing at
a significantly higher rate after day 21 compared with WT
xenograft tumours (Figure 2D; ** p,0.01 to *** p,0.001
comparing the volume of PTGER4 xenograft tumours versus
WT xenograft tumours). We confirmed elevated PTGER4
Table 3. Sequences of Taqman primers and probe.
Gene
Symbol Position Nucleotide Sequence (59-39)
HIF-1a Forward CGC ATC TTG G ATA AGG CCT CTG T
Reverse AAT CAC CAG G CAT CCA GAA GTT TC
PTGER1 Forward AGA TGG TGG GCC AGC TTG T
Reverse GCC ACC AAC ACC AGC ATT G
PTGER2 Forward GAC CGC TTA CCT GCA GCT GTA C
Reverse TGA AGT TGC AGG CGA GCA
PTGER3 Forward GAC GGC CAT TCA GCT TAT GG
Reverse TTG AAG ATC ATT TTC AAC ATC ATT ATC A
PTGER4 Forward ACG CCG CCT T ACT CCT ACA TG
Reverse AGA GGA CGGG TGG CGA GAA T
PTGES Forward TCA ACT GTG G ATG GCA AGA GC
Reverse CTA ACC TCC C TGA GCC CTC CT
PTGES1 Forward CGG AGG CCC CCA GTA TTG
Reverse GGG TAG ATG GTC TCC ATG TCG TT
PTGES2 Forward CCT CAT CAG CAA GCG ACT
Reverse CCA CTT GTC AGC AGC CTC A
doi:10.1371/journal.pone.0019209.t003
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PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e19209Figure 1. Expression profile of the PTGES-PTGER system in endometrial adenocarcinoma and normal endometrium. mRNA
expression of PGE2 synthase isoforms (PTGES, -2, -3) and E-series prostaglandin receptors (PTGER1–4) in normal endometrium (n=40; comprising
a pool of proliferative n=10; early secretory n=10; mid-secretory n=10 and late secretory n=10 phase endometrium) and endometrial cancer
(n=29; comprising a pool of poorly differentiated n=10, moderately differentiated n=10 and well differentiated endometrial adenocarcinoma n=9).
**, *** represent significance at P,0.01 and P,0.001 for cancer vs normal.
doi:10.1371/journal.pone.0019209.g001
Figure 2. PTGER4 enhances tumour growth in a nude mouse xenograft model. (A) PTGER4 mRNA expression in WT Ishikawa cells
compared with Ishikawa cells stably transfected with the full length PTGER4 cDNA transcript (n=3). (B) Immunolocalisation of PTGER4 expression in
WT and PTGER4 stable cell lines. (C) cAMP accummulation in WT and PTGER4 stable cell lines in response to treatment with 100 nM PGE2 for 0 or
5 minutes (n=3). (D) Tumour growth in CD1-Foxn1
nu mice following dorsal flank injection with either Ishikawa WT or PTGER4 stable cells. Tumour
growth in WT (n=20) and PTGER4 (n=20) xenografts was monitored over a 35 day period as described in the methods. (E) PTGER4 (F) PTGS1 and (G)
PTGS2 mRNA expression in either Ishikawa WT (n=10) or PTGER4 (n=10) xenograft tumours. **, *** represent significance at P,0.01 and P,0.001.
doi:10.1371/journal.pone.0019209.g002
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WT xenograft tumours by quantitative RT-PCR analysis
(Figure 2E, P,0.001) indicating that expression of the transgene
was maintained in vivo.
Since tumour growth in vivo has been shown to be regulated by
the PTGS-PGE2 pathway [24], we next assessed the expression of
the prostaglandin endoperoxide synthase enzymes responsible for
producing PGE2. We found elevated expression of PTGS2
(Figure 2G, P,0.001) but not PTGS1 (Figure 2F) in PTGER4
xenograft tumours compared with WT tumours.
Xenograft tumour growth in PTGER4 tumours is not due
to enhanced angiogenesis
The PTGS-PG pathway has been shown to promote tumorigen-
esis by enhancing angiogenesis [25,26,27]. We investigated whether
the enhanced growth observed in PTGER4 tumours compared with
WT tumours was a result of increased angiogenesis. We investigated
blood vessel density by immunohistochemistry (Figure 3A) and
quantitative stereology (Figure 3B) using the endothelial cell marker
CD31. We found no difference in immunoreactive staining for
CD31 as a percentage area of the tumour in PTGER4 tumours
compared with WT tumours (Figure 3B). Since VEGF is the
progenitor factor responsible for angiogenesis [28], we investigated
whether VEGF levels were altered between the WT and PTGER4
tumours. Similarly, we found no significant difference in VEGF
mRNAlevelsbetween the two groups,confirming that the enhanced
tumour growth in PTGER4 tumours was not a result of increased
angiogenesis (Figure 3C).
Cellular proliferation is enhanced in PTGER4 xenograft
tumours
We assessed whether the rapid increase in growth and volume
of the PTGER4 tumours compared to WT tumours was due to an
enhanced rate of cellular proliferation of PTGER4 cells in vivo.
Immunohistochemistry (Figure 4A) and quantitative stereology
(Figure 4B) revealed a significant increase in proliferation index in
epithelial cells as observed by incorporation of BrdU in PTGER4
tumours compared with WT tumours (Figure 4B, P,0.05).
Furthermore we found no alteration in tumour cell density per
unit area between PTGER4 tumours and WT tumours
(Figure 4C). This suggests that the larger PTGER4 tumours were
a result of hyperplasia rather than hypertrophy or non-
proliferative tumour expansion.
PTGER4 xenograft tumours display an increased area of
hypoxia
Hypoxia is a common recognised driver in many solid tumours
and is thought to contribute to development of endometrial
adenocarcinoma [29]. We assessed whether the level of hypoxia
was altered in the tumours. We found PTGER4 tumours to have
increased areas of hypoxia in comparison to WT tumours as
indicated by the immunoreactivity for the Hypoxyprobe, pimoni-
dazole, per area of tumour investigated (Figure 5A and 5B,
P,0.001). Increased tissue hypoxia in the PTGER4 tumours
compared with WT tumours is also supported by quantitative RT-
PCR analysis demonstrating higher expression of the hypoxia
inducible factor HIF1a (Figure 5C, P,0.01).
Figure 3. Differential tumour growth between WT and PTGER4 xenograft tumours is not due to enhanced angiogenesis.
(A) Detection of blood vessels in WT (n=11 sections) and PTGER4 (n=11 sections) xenograft tumours as determined by immuno-staining with the
endothelial cell marker CD31. (B) Quantitative stereology of blood vessel density in WT and PTGER4 xenograft tumours as determined by percentage
area positively stained for CD31. (C) mRNA expression of the angiogenic factor VEGF in WT (n=10) and PTGER4 (n=10) xenograft tumours.
doi:10.1371/journal.pone.0019209.g003
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PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19209Figure 4. Cellular proliferation is enhanced in PTGER4 xenograft tumours. (A) Immunohistochemistry for detection of cellular proliferation
in WT (n=7 sections) and PTGER4 (n=7 sections) xenograft tumours as determined by staining for BrdU incorporation in the nuclei. (B) Quantitative
stereology of cellular proliferation in WT and PTGER4 xenograft tumours as determined by percentage area positively stained for BrdU incorporation
in the cell nuclei. (C) Quantitative stereology of cell density in WT and PTGER4 xenograft tumours as determined by percentage area stained positive
for nuclear counterstain. * represents significance at P,0.05.
doi:10.1371/journal.pone.0019209.g004
Figure 5. PTGER4 xenograft tumours display increased areas of hypoxia compared with WT control. Immunohistochemistry for
detection of hypoxia in WT (n=5 sections) and PTGER4 (n=5 sections) xenograft tumours as determined by staining for the Hypoxyprobe
pimonidazole. (B) Quantitative stereology of hypoxia in WT and PTGER4 xenograft tumours as determined by percentage area stained positive for
Hypoxyprobe. (C) mRNA expression of the hypoxia inducible factor HIF1a in WT (n=10) and PTGER4 (n=10) xenograft tumours. **, *** represents
significance at P,0.01 and P,0.001 for PTGER4 versus WT respectively.
doi:10.1371/journal.pone.0019209.g005
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cellular proliferation
Since we found PTGER4 tumours to have an increased
proliferation index and hypoxia, we investigated the molecular
mechanism regulating PTGER4 expression and proliferation of
PTGER4 cells in vitro and the contribution of hypoxia to this. We
found that treatment of PTGER4 cells with 100 nM PGE2
rapidly induced expression of PTGER4 at all time points
investigated (Figure 6A, P,0.001). Furthermore, we found that
incubation of PTGER4 cells, under hypoxic conditions also
induced PTGER4 mRNA expression (Figure 6B, P,0.001). This
hypoxia-induced expression of PTGER4 was independent of the
PTGS-PG system, as co-incubation of cells with the dual PTGS
enzyme inhibitor indomethacin had no effect on PTGER4
expression induced by hypoxia (Figure 6B, P,0.001). These data
indicate two independent regulators of PTGER4 expression, the
PTGS-PG system and hypoxia induced pathways. Finally we
investigated the impact of PGE2 signaling and hypoxia on
proliferation of PTGER4 cells in vitro. We have shown that
neither PGE2 nor hypoxia alone can promote proliferation of
PTGER4 cells. However, proliferation was significantly elevated
following culture of cells with PGE2 and hypoxia in combination
(Figure 6C, P,0.05).
Discussion
The PTGS-PG pathway is a potent driver of tumorigenesis in
several cancers, including colon, prostate and breast [30,31,32,33].
Expression of PTGS enzymes and biosynthesis of PGE2 is elevated
in cancers of the female reproductive tract, including endometrial
and cervical carcinomas [9,10,34]. These findings indicate that
PGE2, via specific E-series prostanoid receptors may drive the
development and progression of reproductive tract cancer in a
similar manner to other solid tumours.
We undertook a comprehensive analysis of the expression
profile of the PTGES-PGE2-PTGER system in normal endome-
trium across the menstrual cycle and endometrial adenocarcinoma
of all grades. As the endometrium of post-menopausal women is
no longer under normal hormonal control, the tissue is atrophic
and rarely attainable for analysis, we chose normal endometrium
as our comparator. We found a variation in the expression of the
PTGES-PTGER system across the menstrual cycle, as shown in
Figure S1 and is discussed in our recent study [23]. However, of
particular significance to this study was the observation of a
significant increase in expression of PTGER4 in endometrial
cancer compared with normal endometrium across the menstrual
cycle. These findings using a substantially larger sample size are
Figure 6. Mechanism of regulation of cellular proliferation in PTGER4 cells in vitro. (A) PTGER4 mRNA expression in PTGER4 cells treated
with vehicle or 100 nM PGE2 for 2, 4, 6, 8 and 24 hours (n=3). (B) PTGER4 expression in PTGER4 cells grown for 24 hours under normoxic and hypoxic
conditions, in the absence or presence of the PTGS enzyme inhibitor indomethacin (n=4). (C) Cellular proliferation in PTGER4 cells grown for
24 hours under normoxic (N) or hypoxic (H) conditions in the absence or presence of 1 mM PGE2 (n=4). (D) Schematic diagram of findings
demonstrating that hypoxia and PGE2 both independently elevate PTGER4 expression and synergise to enhance proliferation of PTGER4 cells.
*, *** represent significance at P,0.05 and P,0.001 respectively.
doi:10.1371/journal.pone.0019209.g006
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proteins in neoplastic epithelial cells in endometrial cancer [9].
However, more interestingly, within this sample set we found a
significant reduction in the expression patterns of PTGER1 and
PTGER3 in endometrial adenocarcinomas compared with normal
endometrium. These two G protein-coupled receptors differen-
tially couple with Gq and Gi respectively resulting in activation of
inositol 1,4,5 trisphosphate and suppression of cAMP [35]. The
suppression of these receptors and augmentation of PTGER4,
strongly suggest that PGE2, produced via PTGS and PTGES2, is a
driver of endometrial tumour development via the activation of
PTGER4 and initiation of cAMP signalling. Indeed, PTGER4 has
been demonstrated to promote human lung and colorectal cancer
cell growth [30,31]. Moreover antagonism of PTGER4 signalling
with small molecule receptor antagonists or RNA interference has
been shown to inhibit cell growth, proliferation, invasion [33] and
metastasis of breast cancer cells [32].
To determine a role for PTGER4 in endometrial tumour
development, we stably transfected the full length PTGER4 cDNA
transcript into Ishikawa endometrial epithelial cells. We demon-
strated translation and functionality of the PTGER4 transgene in
Ishikawa cells by immunohistochmistry and cAMP assay and
showed that the protein was trafficked to the expected plasma
membrane compartment. We investigated the impact of PTGER4
on endometrial tumour development in vivo using a nude mouse
model. CD1-Foxn1
nu mice were xenografted with WT or PTGER4
cells and xenograft tumour growth was measured over a 35 day
period. We found that PTGER4 cells grew at a faster rate resulting
in tumours of approximately twice the size compared to WT
tumours. Furthermore, higher PTGER4 expression was main-
tained in PTGER4 tumour xenografts compared with xenografts
from WT cells indicating that stability of the transgene was
maintained throughout the duration of the experiment. Interest-
ingly, we found that expression of PTGS2 but not PTGS1 was
elevated in PTGER4 tumour xenografts compared with WT
xenografts. These observations, together with our previous
findings showing elevated expression of PTGS2, PGES2 and
PGE2 in endometrial cancer [9] strongly support a role for PG in
driving endometrial tumorigenesis via the PTGER4-cAMP
pathway similar to observations in colon cancer cells [30,36].
Furthermore, other signalling pathways may synergise with or
augment PTGER4 signalling in vivo to promote the major increase
in proliferation we observed in mice xenografts. For example, we
have recently shown that multiple PG ligands can converge on the
same prostanoid receptor to regulate gene transcription in vitro
[37]. In addition we have shown that the PTGER2 and PTGFR
receptors can crosstalk via the Gs and Gq pathways to enhance
cAMP signalling and target gene transcription in endometrial
adenocarcinoma cells in vitro [38]. It is plausible that similar
mechanisms may regulate PTGER4 signalling in vivo to promote
endometrial tumour cell growth.
Elevated PTGS2 expression and PGE2 biosynthesis and
signalling has been shown to promote tumorigenesis by enhancing
expression of angiogenic factors such as VEGF and increasing
angiogenesis [27,39]. We investigated whether the enhanced
growth rate and tumour size in the PTGER4 xenografts compared
with WT was due to an enhancement in the elaboration of
vascular network to support tumour growth by enhancing nutrient
supply and oxygen. However, surprisingly we found no difference
in the blood vessel density between the PTGER4 compared with
WT tumours as indicated by staining for the endothelial cell
marker CD31 or expression of vascular endothelial growth factor.
These findings indicate that the observed increase in tumour
growth between WT and PTGER4 xenografts was not a
consequence of enhanced angiogenesis.
Endometrial cancer growth at the invasive front is regulated by
a higher rate of cellular proliferation, driven by the alteration in
cell cycle regulation [40,41]. Although PGE2 has been shown to
inhibit cellular proliferation in certain cell types [42], blockade of
PTGER4 expression inhibits both proliferation and invasion of
human inflammatory breast cancer cells [33]. Moreover, alter-
ation in cell cycle regulation and cellular proliferation is known to
be regulated in colon cancer cells by the PTGS-PG-PTGER4
pathway [11,36]. In accordance with these observations, we have
found that the elevated growth rate of PTGER4 xenograft
tumours in our study is mediated by an increase in the rate of
cellular proliferation as indicated by an increase in the
incorporation of BrdU in the nuclei of PTGER4 tumour
xenografts compared with WT xenografts. Furthermore, we
confirmed that the tumour growth was mediated by hyperplasia,
rather than hypertrophy or non-proliferative tumour expansion
such as enhanced cell migration, since we found no difference in
the density of cells in PTGER4 xenograft tumours compared with
WT tumours.
Since we found no alteration in angiogenesis, but rather an
increase in cellular proliferation, we hypothesised that the
PTGER4 xenograft tumours had a higher metabolic demand
compared with WT tumours. This would impose higher oxygen
and nutrient requirement, which coupled with absence of an
increase in angiogenesis, would result in increased hypoxia. Since
energy metabolism in cancer cells is regulated in part by hypoxia
[43], and hypoxia is a well known driver of tumorigenesis, we
investigated levels of hypoxia between the two groups. We found
that the PTGER4 xenograft tumours had increased areas of
hypoxia as determined by the immunoreactivity for the hypoxy-
probe pimonidazole per area of tumour investigated. Moreover we
found elevated expression of the hypoxia inducible factor HIF1a
in PTGER4 xenografts. Hypoxia inducible factors are well
recognised drivers in the tumour microenvironment. They have
been shown to induce VEGF expression to promote angiogenesis
and tumorigenesis [44]. Furthermore, HIF1a is induced by low
oxygen levels and is elevated in fast growing tumours and can
activate the inflammatory PTGS-PG system and enhance cellular
proliferation [43,45]. Although we didn’t find a correlation with
hypoxia and VEGF between the WT and PTGER4 xenografts in
our study, it is plausible that hypoxia can induce VEGF equally in
both groups early on during tumour growth independent of
PTGER4 when vascular networks are forming. Since we didn’t
find any difference in VEGF expression between WT and
PTGER4 xenografts at the time of analysis, it is possible that
VEGF regulation by hypoxia in WT and PTGER4 xenografts was
already at maximal at the time of analysis in our study.
Our in vivo data suggest that endometrial adenocarcinoma
growth is regulated by the PTGER4 pathway and hypoxia. To
investigate the mechanism and crosstalk whereby PTGER4 and
hypoxia could regulate cellular proliferation in endometrial
adenocarcinoma cells, we used our PTGER4 stable cell line in
vitro. We found that PGE2 could induce expression of PTGER4,
indicating a positive feedback system induced by the PTGS-PGE2
synthase-PGE2 pathway to maintain PTGER4 expression. Fur-
thermore we found that under conditions of low oxygen tension,
PTGER4 expression could similarly be induced independently of
the PTGS-PG system. These findings indicate two independent
pathways which could drive elevated expression of PTGER4.
Perhaps most strikingly, we found that neither pathway alone
could significantly induce cellular proliferation, but were required
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schematically in Figure 6D.
Taken together, our data for the first time highlight a role for
PTGER4 in endometrial tumour development. Furthermore our
data propose a novel molecular mechanism whereby PGE2
biosynthesis, driven by elevated expression of PTGS2 in
endometrial adenocarcinoma cells, and hypoxia synergise to
increase PTGER4 expression and subsequently enhance cell
proliferation and tumour growth.
Supporting Information
Figure S1 Expression profile of the PTGES-PTGER
system in endometrial adenocarcinoma and normal
endometrium. mRNA expression of PGE2 synthase isoforms
(PTGES, -2, -3) and E-series prostaglandin receptors (PTGER1–4)
in normal endometrium (n=40; comprising of proliferative n=10;
early secretory n=10; mid-secretory n=10 and late secretory
n=10 phase endometrium) and endometrial cancer (n=29;
comprising poorly differentiated n=10, moderately differentiated
n=10 and well differentiated endometrial adenocarcinoma n=9).
*, **, *** represent significance at P,0.05, P,0.01 and P,0.001.
(TIF)
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